Healthcare Business

Momenta Pharma (MNTA) Down 46%

Shares of Momenta Pharma (MNTA) are off 46% to $7.27, a 52-week low. The company said said Tuesday the Food and Drug Administration denied approval for its blood clot drug enoxaparin sodium, being developed with partner Novartis.

Douglas A. McIntyre

Mo